Microdosing Tirzepatide: Chart, Schedule & Who It's For
Microdosing tirzepatide — using doses below 2.5 mg weekly — is an off-label strategy for sensitive responders, side-effect management, and maintenance dosing after reaching goal weight. Here's the chart, the math, and the trade-offs.
Microdosing tirzepatide is not FDA-approved and is not in any official prescribing guideline. It must be authorized and supervised by a licensed prescriber. Never modify your prescribed dose without medical guidance. This guide is informational only.
01 What is microdosing tirzepatide?
Microdosing tirzepatide is the practice of using weekly doses below the FDA-labeled starter dose of 2.5 mg. In practical terms, that usually means injecting 0.5 mg, 1 mg, 1.5 mg, or 2 mg per week instead of 2.5 mg or higher. Some patients also "microdose by interval" — taking the standard 2.5 mg dose every 10 to 14 days instead of every 7.
The strategy emerged from real-world telehealth experience as patients reported a wide spectrum of sensitivity to tirzepatide. Some get full appetite suppression at 1 mg/week and don't need anything higher. Others tolerate 2.5 mg poorly, with prolonged nausea and vomiting that resolves at lower doses. And a third group reaches goal weight on 5–10 mg and wants to step down to maintain the benefit with less drug.
Microdosing is genuinely off-label. Eli Lilly has not produced sub-2.5 mg pens because the official Zepbound trial program started at 2.5 mg as a tolerance dose. There are no published phase 3 trials of sub-2.5 mg tirzepatide. What exists is anecdotal evidence from telehealth practice, a small number of case reports, and a lot of Reddit threads.
02 Microdosing tirzepatide chart
At the most common compounded concentration of 5 mg/mL, the relationship between mg, mL, and U-100 units looks like this:
| Microdose level | Weekly dose | Units (5 mg/mL) | % of standard 5 mg |
|---|---|---|---|
| Ultra-low | 0.5 mg | 10 units | 10% |
| Very low | 1.0 mg | 20 units | 20% |
| Low | 1.5 mg | 30 units | 30% |
| Moderate | 2.0 mg | 40 units | 40% |
| Standard starter | 2.5 mg | 50 units | 50% |
Conversions assume a 5 mg/mL concentration. At 10 mg/mL, halve the unit numbers; at 15 mg/mL, divide by three.
Higher-concentration vials
Microdosing with very dilute vials (5 mg/mL) gives you more measurable draws. With a 10 mg/mL vial, a 0.5 mg microdose is just 5 units — at the edge of insulin syringe accuracy. If you plan to microdose, ask your compounding pharmacy for the lower-concentration option.
03 Microdosing schedule example
There is no standardized microdosing schedule. Below is one of the more conservative approaches used in telehealth practice — discuss with your prescriber before adapting.
| Phase | Weekly dose | Duration | Goal |
|---|---|---|---|
| Initiation | 0.5 mg | 2 weeks | Tolerance at minimal exposure |
| Step up | 1.0 mg | 2 weeks | Initial appetite assessment |
| Step up | 1.5 mg | 2–4 weeks | Sensitive responders may stop here |
| Step up | 2.0 mg | 4+ weeks | Common low-end maintenance |
| Standard starter | 2.5 mg | 4+ weeks | If microdoses inadequate, transition to standard |
Maintenance microdosing
For patients at goal weight who reached it on 5 mg or higher, a common maintenance pattern is to step down by 25–50% and assess monthly. For example: 10 mg → 5 mg → 2.5 mg → 1.5 mg, holding each step for 4–8 weeks and watching for return of food noise or weight regain. The lowest dose that maintains your goal weight is your maintenance dose. Some patients can maintain on 1–2 mg/week; others need to stay closer to their loss-phase dose.
04 Who is microdosing tirzepatide for?
Good candidates
- Severe nausea/vomiting at 2.5 mg that doesn't resolve
- Sensitive responders who get full appetite effect at 1–2 mg
- Patients at goal weight stepping down from a higher dose
- Petite, low-BMI patients (BMI 27–30) with mild metabolic goals
- Those wanting minimal medication exposure long-term
Probably not a fit
- Severely obese patients early in treatment (BMI 40+)
- Patients with poorly controlled type 2 diabetes
- Anyone trying to "make a vial last longer" without medical oversight
- Patients losing <0.5 lb/week — usually the answer is more dose, not less
- Anyone using brand pens (you can't subdivide them)
05 Pros and cons of microdosing
Potential benefits
- Fewer side effects. GI symptoms are dose-dependent. Lower dose = generally fewer and milder symptoms.
- Lower cost (in theory). One vial lasts longer if you're drawing smaller doses. In practice, many providers price by month not by mg, so the savings is limited.
- Slower, gentler weight loss — for patients who don't want or need rapid loss.
- Maintenance flexibility. Easier to step down gradually after reaching goal weight than to jump from 10 mg to nothing.
- Lower muscle loss risk in theory — slower weight loss pace generally preserves more lean mass.
Real downsides
- Sub-therapeutic for many. Most patients need at least 5 mg to see meaningful weight loss.
- No clinical trial evidence. The 20.9% weight loss number from SURMOUNT-1 came from 15 mg dosing, not 1 mg.
- Off-label. Your prescriber must specifically authorize it — many won't.
- Measurement precision matters. Drawing 5 units accurately on a U-100 syringe is harder than drawing 50 units.
- Vial waste with brand vials. Brand-name single-dose vials are not designed for partial use.
06 Microdose math (the formula)
Units to draw = (target microdose in mg ÷ vial concentration in mg/mL) × 100
Example 1: Target 1 mg. Vial concentration 5 mg/mL. → (1 ÷ 5) × 100 = 20 units.
Example 2: Target 0.5 mg. Vial concentration 10 mg/mL. → (0.5 ÷ 10) × 100 = 5 units. (Note: 5 units is at the edge of accurate measurement on most U-100 insulin syringes — this is where lower concentrations help.)
Example 3: Target 1.5 mg. Vial concentration 5 mg/mL. → (1.5 ÷ 5) × 100 = 30 units. Easier to measure precisely.
For dosing math at any combination of mg, vial size, and BAC water amount, see the reconstitution calculator — it handles microdose math by selecting a smaller target dose.
Get tirzepatide with flexible dosing.
Compounded tirzepatide telehealth providers can prescribe and ship the multi-dose vials needed for microdosing. Discuss your dose preference with your provider during the consult.
Find a Provider→07 Microdosing tirzepatide FAQ
Microdosing tirzepatide refers to using doses below the FDA-labeled starter dose of 2.5 mg/week — typically anywhere from 0.5 mg to 2.0 mg weekly. It is an off-label dosing strategy used by patients who experience strong side effects at the standard starter dose, those who want to maintain weight loss with minimal medication, or sensitive responders who get adequate appetite suppression at sub-therapeutic doses.
Generally, anything below 2.5 mg per week. The FDA-labeled starter dose is 2.5 mg, and that's already considered a tolerance dose (not a therapeutic weight-loss dose) by Eli Lilly. Microdosing means going lower still — most commonly 0.5, 1.0, 1.5, or 2.0 mg weekly. Some patients also microdose by spacing standard doses every 10–14 days instead of every 7.
You draw fewer units on your insulin syringe than the standard schedule calls for. For a vial reconstituted to 5 mg/mL, common microdose draws are: 10 units (0.5 mg), 20 units (1 mg), 30 units (1.5 mg), or 40 units (2 mg). Use the same once-weekly schedule. Your prescriber must specifically authorize and instruct you in microdosing — it's an off-label modification.
Less effective than standard dosing in clinical-trial terms, but real-world results vary. Some sensitive responders lose meaningful weight at 1–2 mg weekly. Others see no appetite effect below 2.5 mg. There are no published phase 3 trials of sub-2.5 mg tirzepatide. The strongest case for microdosing is in maintenance after reaching goal weight, not as a primary weight-loss strategy.
Three main reasons: (1) Side effects — some patients tolerate 1 mg fine but vomit at 2.5 mg; (2) Sensitivity — a minority of patients get full appetite suppression at sub-therapeutic doses; (3) Maintenance — patients at goal weight who want to keep the appetite benefit without the cost or side-effect load of full dosing. A fourth, less recommended reason is cost stretching (making one vial last longer).
There is no standardized schedule because microdosing is off-label. The most common pattern is to start at 0.5 or 1 mg weekly for 2–4 weeks, then increase by 0.5 mg every 2–4 weeks until you find the lowest effective dose. Many patients stay at 1.5–2 mg weekly long-term. Always discuss with your prescriber — do not self-modify your dose.
No — the Mounjaro and Zepbound auto-injector pens deliver fixed doses (2.5, 5, 7.5, 10, 12.5, or 15 mg). They cannot be split or partially dosed. Microdosing requires either the brand-name single-dose vial (Lilly Direct) or compounded multi-dose vials, drawn with an insulin syringe.
Related
Standard dosing →
FDA-labeled dosing chart and titration schedule.
Compounded tirzepatide →
Reconstitution math and concentration options for microdosing.
Side effects →
The reason most people consider microdosing in the first place.